Diabetes is a global health crisis. The number of people with type 2 diabetes (T2D) worldwide was estimated at 425 million in 2017 and is projected to increase to 629 million by 2045.1 The increased risk for cardiovascular complications in patients with diabetes is well established, and is generally associated with an increased prevalence of known risk factors such as hypertension, dyslipidaemia and obesity.2 However, the increased risk of cardiovascular disease (CVD) in patients with T2D cannot be attributed solely to these traditional risk factors. The poor control of the majority of cardiovascular risk factors in this patient population3 suggests the need for earlier screening of at-risk patients. A variety of screening tools have been validated, but comprehensive screening is not available in many low- or middle-income countries.4 There remains a need for simple and reliable methods to identify patients with T2D who are most at risk of developing CVD.
The ankle-brachial index (ABI) is the ratio of systolic blood pressure at the ankle to that in the arm. The precise technique and calculation of the ABI have not been standardised, but the usual approach is to measure systolic pressure in both arms and at the posterior tibial and dorsalis pedis arteries in each ankle with the patient in a supine position. The ABI for each leg is then calculated as the higher pressure at the ankle divided by the higher of the left or right arm pressures.5 A number of studies have found that a low ABI is independently associated with increased risk of CVD in patients with peripheral arterial disease (PAD).6 As a result, ABI has been investigated as a predictor of CVD in other high-risk populations. In a population-based cohort study, a low ABI was found to predict an increased risk of CVD independent of the metabolic syndrome and conventional cardiovascular risk factors.7 The ABI has been recommended as one of the most feasible screening methods for CVD in patients with PAD since the equipment is inexpensive, examination takes only around 15 minutes, including a 5-minute pre-test rest in the supine position, and can be performed easily by a nurse.8
However, the accuracy of the ABI may be compromised in people with diabetes due to peripheral arterial stiffening in the ankles. Stiffening of toe arteries rarely occurs in diabetes; therefore, the toe-brachial index (TBI) appears to be a more useful measure in patients with T2D.9-12 Both manual and automatic testing techniques for measuring toe pressure are available and recommendations for their use are emerging.12 Automated systems such as the SysToe (Atys Medical, Soucieu en Jarrest, France) and MicroLife (MicroLife, Taipei, Taiwan) devices have shown high inter-rater reliability.13
There is limited research exploring the reliability of toe systolic pressures and TBIs in patients with T2D, particularly with regard to newer, more affordable devices for measuring toe pressure. A small study has established the utility of TBI in predicting recurrence of CVD in 81 patients with T2D and established ischemic heart disease.14 In another prospective study involving 200 participants with T2D and microalbuminuria, over a median follow-up of 6.1 years, reduced TBI and ABI were associated with increased risk of CVD and all-cause mortality.15
At the 20th European Congress of Endocrinology (ECE), which was held on the 19–22 May 2018 in Barcelona, Spain, a study was presented that aimed to test the predictive value of TBI as a marker for the risk of major adverse cardiovascular events (MACE) in patients with T2D.16 The study involved 741 participants in the CARDIPP epidemiological study (Cardiovascular Risk Factors in Patients with Diabetes-a Prospective Study in Primary Care; NCT010497377). In addition to TBI, investigators measured conventional risk markers for CVD and non-invasive measurements for arterial stiffness: carotid-femoral pulse-wave velocity (PWV, with applanation-tonometry) and intima-media thickness of carotid arteries (IMT, with B-mode ultrasound). During the 7-year follow-up, 74 patients died or were hospitalised for MACE. The TBI tertiles 1 versus 3 levels were found to be negatively correlated with MACE (hazard ration [HR] for each unit of TBI 3.02, confidence interval [CI] 1.71–5.99; p<0.001). The predictive value of TBI was independent of age, sex, diabetes duration and treatment, anti-hypertensive treatment, previous CVD, glycated haemoglobin, low-density lipoprotein cholesterol, estimated glomerular filtration rate, and mean ambulatory systolic blood pressure (HR 3.16, CI 1.50–6.70; p=0.003). Low TBI levels also predicted MACE when carotid-femoral PWV, atherosclerosis plaque identification, and IMT were added to the previous model (HR 3.12, CI 1.32–7.35; p=0.009).16
In summary, this study has added substantially to the growing body of evidence in support of the use of TBI as a predictive tool for the incidence of MACE in patients with T2D. In order to expand the role of TBI into a screening vascular test applicable to all patients with T2D, there is a need to establish cut-off values to identify high risk patients. This study was not designed to establish diagnostic cut-off values, and additional trials will be needed to validate these limits, once established. In addition, large-scale trials will be needed to establish the risk of MACE and mortality in patients with T2D for the various diagnostic limits of TBI.
Publication Date: 30 May 2018
1. International Diabetes Federation, IDF Diabetes Atlas, English Edition 2017. Available at: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-editionhtml (accessed 24 May 2018).
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.
3. del Canizo-Gomez FJ, Moreira-Andres MN. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Res Clin Pract. 2004;65:125-33.
4. Bwititi PT, Nwose EU, Screening of cardiovascular disease risk in diabetes: questions concerning prediabetes and low-mid income countries, N Am J Med Sci, 2014;6:284–6.
5. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.
6. Lin JS, Olson CM, Johnson ES, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In (eds.): The Ankle Brachial Index for Peripheral Artery Disease Screening and Cardiovascular Disease Prediction in Asymptomatic Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force, Rockville, MD: Agency for Healthcare Research and Quality (US), 2013.
7. Wild SH, Byrne CD, Smith FB, et al. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care. 2006;29:637–42.
8. Criqui MH, Alberts MJ, Fowkes FG, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation. 2008;118:2830–6.
9. Hyun S, Forbang NI, Allison MA, et al. Ankle-brachial index, toe-brachial index, and cardiovascular mortality in persons with and without diabetes mellitus. J Vasc Surg. 2014;60:390–5.
10. Sahli D, Eliasson B, Svensson M, et al. Assessment of toe blood pressure is an effective screening method to identify diabetes patients with lower extremity arterial disease. Angiology. 2004;55:641–51.
11. Park SC, Choi CY, Ha YI, et al. Utility of toe-brachial index for diagnosis of peripheral artery disease. Arch Plast Surg. 2012;39:227–31.
12. Hoyer C, Sandermann J, Petersen LJ, The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg. 2013;58:231–8.
13. Sonter J, Sadler S, Chuter V. Inter-rater reliability of automated devices for measurement of toe systolic blood pressure and the toe brachial index. Blood Press Monit. 2015;20:47–51.
14. Martin-Fuentes M, Herranz L, Saez-de-Ibarra L, et al. Low toe-brachial pressure index predicts increased risk of recurrent cardiovascular disease in type 2 diabetes. Diabetes Care. 2015;38:e53–4.
15. Zobel EH, von Scholten BJ, Reinhard H, et al. Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. Diabetologia. 2017;60:1883–91.
16. Chisalita IS, Wijkma, M., Chong, Lee T et al. Toe brachial index predicts major adverse cardiovascular events in patients with type 2 diabetes. Endocrine Abstracts. 2018;56:OC4.2 | DOI: 10.1530/endoabs.56.OC4.2.
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!